Amylyx Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Amylyx Pharmaceuticals

05/08/2025 15:03

Amylyx Pharmaceuticals Inc AMLX.OQ AMLX.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

​LSEG's mean analyst estimate for Amylyx Pharmaceuticals Inc is for a loss of 45 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Amylyx Pharmaceuticals Inc is $10.00, about 20.4% above its last closing price of $7.96

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.48
-0.47
-0.42
Beat
11.6
Dec. 31 2025
-0.52
-0.52
-0.55
Missed
-5.8
Sep. 30 2024
-0.75
-0.71
-1.07
Missed
-50.7​
Jun. 30 2024
-0.64
-0.73
-0.73
Met
0
​​Mar. 31 2024
0.02
-0.01
-0.12
Missed
-1,900
Dec. 31 2023
0.24
0.23
0.07
Missed
-69.3​
Sep. 30 2023
0.43
0.44
0.30
Missed
-31
Jun. 30 2023
0.08
0.10
0.31
Beat
210

This summary was machine generated August 5 at 14:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)